Oct 2013 |
Press Release |
NeuroAiD™, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke
Singapore, 21st October 2013 – Early vascular events are an important cause of morbidity and mortality in the first three months after a stroke. The CHIMES Study is a placebo-controlled trial of NeuroAiD™, having included 1099 patients with ischemic stroke and receiving appropriate secondary prevention treatments. The frequency of early cardiovascular events and deaths during the 3-month follow-up was significantly halved in the NeuroAiD™, group (p=0.025) without an increase in bleeding rate and non-vascular deaths. |
EN |
|
Jul 2013 |
Radio Interview |
Presenter of ‘Body & Soul’ program on 938LIVE Daniel Martin interviews Prof Christopher Chen on Stroke in Singapore and the CHIMES Study.
938LIVE is a poplar news-focused radio station. ‘Body & Soul’, since it first aired in 2007, has been Singapore’s only dedicated daily health radio talk-show. |
EN |
|
Jun 2013 |
Press Release |
Stroke Treatment based on Traditional Chinese Medicine increases chances of recovery
- CHIMES Society, a unique international partnership of experts in strokes undertakes first large-scale endeavour to investigate the use of a treatment derived from natural substances in stroke management.
- Rigorous study shows ischemic stroke patients of intermediate severity who take NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence and being able to perform daily activities at the end of three months.
- Effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.
|
EN |
|
Mar 2013 |
Press Release |
NeuroAiD™, a stroke treatment based on traditional Chinese medicine, more than doubles the chances of achieving independence after stroke
Singapore, March 19 2013: Authors of a medical paper published in this month’s Cerebrovascular Diseases journal found that NeuroAiD™ significantly improves patients’ independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely. The study also showed that NeuroAiD™ improved patients’ chances of performing daily activities after stroke. |
EN |
|
Jan 2013 |
Media Coverage |
NurAiD™II is featured on France 24 with an interview with neurologist and prescriber Dr Charles Siow, CEO David Picard and lead investigator of the CHIMES trial Prof Christopher Chen about bringing Chinese medicine into the Western standards to fill the gap of improving recovery after stroke. |
EN |
|